ARCHIVES

FDA Designates Zometa For Priority Review.

This article is from The Cancer Letter archive.

Vol. 27 No. 44 | November 30, 2001

Download PDF Visit The Full Archive

Related Articles

Edelson To Step Down As Yale Center Director.

January 11, 2008

Cancer Organizations Continue Reform Lobbying: Target Issue Are Off-Label Drugs, Clinical Trials

March 26, 1993

In Brief: Administration “Streamlining” Accomplished; DCCR contract Merit Review In Open Session

February 24, 1978

ACR Survey Finds Radiologist Change Mammography Methods

April 3, 1987

Oncology Groups Oppose Proposed Cuts In Medicare Payments For Cancer Drugs

October 11, 2002

UCSF Gets $20 Million For Stem Cell Research Building

February 4, 2011